Timothy Pardee
Hematology & Oncology · Winston Salem, NCNPI 1740386010
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.8%. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $1338.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$16K
- AbbVie$10K
- Ipsen Innovation$9K
- Amgen$9K
- Pharmacyclics LLC, An Abbvie Company$7K
- Johnson & Johnson$6K
- plus $12K from 7 others
Across 105 payments — averaging $5127.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Karyopharm Therapeutics Inc.$173K
- Sumitomo Pharma America, Inc.$111K
- Amgen$96K
- Astellas Pharma Global Development$42K
- Syndax Pharmaceuticals, Inc.$41K
- Bayer$31K
- plus $44K from 2 others
What the payments were for
- Consulting fees$39,21057%
- Speaking & faculty fees$25,25037%
- Travel & lodging$2,6494%
- Food & beverage$1,1372%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 7 | $15,535 |
| AbbVie | 11 | $10,257 |
| Ipsen Innovation | 4 | $9,095 |
| Amgen | 7 | $9,018 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $6,690 |
| Johnson & Johnson | 2 | $5,500 |
| Karyopharm Therapeutics Inc. | 2 | $4,000 |
| AstraZeneca | 1 | $2,740 |
| Syndax Pharmaceuticals, Inc. | 2 | $2,650 |
| Genentech USA, Inc. | 4 | $2,359 |
| Gilead(2 entities) | 5 | $381 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| RARE Disease Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,245 in reported general payments places this provider in the 90th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levofloxacin | 12 | $108 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Winston Salem
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Caio Max Rocha LimaWinston Salem$110K
- Leon Bernal-MizrachiWinston Salem$62K
- Matthew WieduwiltWinston Salem$36K
- John McKayWinston Salem$22K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.